Activation B7-1 antigen, LAB7, T-lymphocyte activation antigen CD80, CD80 Molecule, CD80 Antigen (CD28 Antigen Ligand 1, B7-1 Antigen), B-Lymphocyte Activation Antigen B7, CTLA-4 Counter-Receptor B7.1, CD28LG1, BB1, Costimulatory Molecule Variant IgV-CD80, Costimulatory Factor CD80, CD80 Antigen, B7-1, B7.1, B7-1 Antigen, B7, CD80, CD28LG


Cluster of differentiation 80 (also CD80 and B7-1) is a B7, type I membrane protein that is in the immunoglobulin superfamily, with an extracellular immunoglobulin constant-like domain and a variable-like domain required for receptor binding. It is involved in the costimulatory signal essential for T-lymphocyte activation. T-cell proliferation and cytokine production is induced by the binding of CD28, binding to CTLA-4 has opposite effects and inhibits T-cell activation.

KO Status

RenMab: Immunization

RenLite: F0

Drug Information

Launched drugs: 2
Drugs in clinical trials: 3
Latest Research Phase: Approved

Drug Name





Clinical Trials


BMS-188667, BMS-188667SC, ONO-4164SC, ONO-4164


Bristol-Myers Squibb Company

Polymyositis, Myositis, Dermatomyositis, Coronavirus Disease 2019 (COVID-19), Arthritis, Rheumatoid, Sjogren's Syndrome, Arthritis, Juvenile, Lupus Nephritis, Multiple Sclerosis, Nephrosis, Lipoid, Lupus Erythematosus, Systemic, Psoriasis, Glomerulosclerosis, Focal Segmental, Arthritis, Psoriatic, Colitis, Ulcerative, Muscular Diseases, Nephrotic Syndrome, Crohn Disease


LEA29Y, LEA-029, BMS-224818, L104EA29YIg


Bristol-Myers Squibb Company

Rejection of renal transplantation, Rejection of organ transplantation

Belatacept biosimilar (Alphamab)


Phase 2 Clinical

Suzhou Alphamab Co Ltd

Rejection of renal transplantation, Arthritis, Rheumatoid, Autoimmune Diseases

Chimeric antigen receptor T-cell therapy (Hunan Zhaotai Yongren Biotech)


Phase 1 Clinical

Hunan Zhaotai Yongren Biotech

Carcinoma, Non-Small-Cell Lung

rVV-740CTA vaccine (University Hospital Basel)


Phase 1 Clinical

University Hospital Basel

Breast Neoplasms

Recombinant canarypox virus-based vaccine (Sanofi Pasteur)



Therion Biologics, Sanofi Pasteur

Colorectal Neoplasms, Melanoma

Abatacept biosimilar (Momenta Pharmaceuticals)




Autoimmune Diseases, Inflammation

Recombinant human CTLA4-Ig Fusion protein(Shanghai CP Guojian)


Shanghai Cp Guojian Pharmaceutical Co Ltd

Arthritis, Rheumatoid

Abatacept biosimilar (Hanwha Biologics)


Hanwha Biologics






Arthritis, Rheumatoid





B7, a new member of the Ig superfamily with unique expression on activated and neoplastic B cells

Freeman G.J., Freedman A.S., Segil J.M., Lee G., Whitman J.F., Nadler L.M.,

J. Immunol. 143:2714-2722(1989)

Genomic organization and chromosomal location of the human gene encoding the B-lymphocyte activation antigen B7

Selvakumar A., Mohanraj B.K., Eddy R.L., Shows T.B., White P.C., Dupont B.,

Immunogenetics 36:175-181(1992)

Human Soluble CD80 is generated by alternative splicing, and recombinant soluble CD80 binds to CD28 and CD152 influencing T-cell activation

Kakoulidou M., Giscombe R., Zhao X., Lefvert A.K., Wang X.,

Scand. J. Immunol. 66:529-537(2007)

The DNA sequence, annotation and analysis of human chromosome 3

Muzny D.M., Scherer S.E., Kaul R., Wang J., Yu J., Sudbrak R., Buhay C.J., Chen R., Cree A., Ding Y., Dugan-Rocha S., Gill R., Gunaratne P., Harris R.A., Hawes A.C., Hernandez J., Hodgson A.V., Hume J., Gibbs R.A.,

Nature 440:1194-1198(2006)

The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC)

The MGC Project Team,

Genome Res. 14:2121-2127(2004)

Structure, expression, and T cell costimulatory activity of the murine homologue of the human B lymphocyte activation antigen B7

Freeman G.J., Gray G.S., Gimmi C.D., Lombard D.B., Zhou L.-J., White M., Fingeroth J.D., Gribben J.G., Nadler L.M.,

J. Exp. Med. 174:625-631(1991)

CD80 (B7) and CD86 (B70) provide similar costimulatory signals for T cell proliferation, cytokine production, and generation of CTL

Lanier L.L., O'Fallon S., Somoza C., Phillips J.H., Linsley P.S., Okumura K., Ito D., Azuma M.,

J. Immunol. 154:97-105(1995)

Interaction of CTLA-4 (CD152) with CD80 or CD86 inhibits human T-cell activation

Vandenborre K., Van Gool S.W., Kasran A., Ceuppens J.L., Boogaerts M.A., Vandenberghe P.,

Immunology 98:413-421(1999)

Members of adenovirus species B utilize CD80 and CD86 as cellular attachment receptors

Short J.J., Vasu C., Holterman M.J., Curiel D.T., Pereboev A.,

Virus Res. 122:144-153(2006)

Toward a comprehensive characterization of a human cancer cell phosphoproteome

Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., Mohammed S.,

J. Proteome Res. 12:260-271(2013)